Search results

  1. V

    Effects of Motor Imagery on Movement-Based Fear in Musculoskeletal Conditions: A Critically Appraised Topic, 2026, Pearcy et al

    @Sean, my apologies. I know better. I couldn’t read it either. I tried using the "paper formater” software that some nice person (whose name I forgot) here on the forum created to make the process of posting a paper easier and I did not review that mass of text for readability. Thanks for...
  2. V

    Problems arising for pwME from additional diagnoses of MCAS, hEDS and POTS. Advocacy discussion.

    @Jonathan Edwards, I should know better than to question your diagnostic descriptions , but did the "chronic widespread unexplained pain" include joint pain? I always assumed the fibromyalgia diagnosis excluded joint pain and was chronic widespread unexplained neuromuscular pain, but I am a lay...
  3. V

    Effects of Motor Imagery on Movement-Based Fear in Musculoskeletal Conditions: A Critically Appraised Topic, 2026, Pearcy et al

    Effects of Motor Imagery on Movement-Based Fear in Musculoskeletal Conditions: A Critically Appraised Topic Abstract Clinical Scenario : The presence of movement-based fear during rehabilitation negatively impacts injury recovery, quality of performance, and perceived disability. While...
  4. V

    Do you have any ideas for topics for PRIME seminars?

    How about a discussion of pros and cons of (and engaging of interest in) a world-wide whole genome sequencing study?
  5. V

    Do you have any ideas for topics for PRIME seminars?

    FWIW, in DecodME 86.1% of the cohort reported "muscle pain".
  6. V

    Ligaments and tendons

    Ranma, My original symptoms also started as repetitive stress symptoms from keyboard and mouse overuse.
  7. V

    Uncovering the genetic architecture of ME/CFS: a precision approach reveals impact of rare monogenic variation, 2025, Birch, Younger et al

    @LizWorthey, I am reading your interchanges with great interest. Thanks for participating. FYI, here is the thread on S4ME on FBXL4: https://www.s4me.info/threads/genetics-fbxl4.45509/
  8. V

    Navigating the Health Insurance system in the USA.

    This is a long video about the current intricacies of the United States healthcare system and the realities of appealing a denial of service by your health insurance company. The man being interviewed, Warris Bokhari, has started a company that uses AI to prepare a appeal to a denial of...
  9. V

    Associations Between Genetic Polymorphisms and Psychological Variables in Women With Fibromyalgia: A Cross‐Sectional Study, 2025, Riquelme‐Aguado….

    Associations Between Genetic Polymorphisms and Psychological Variables in Women With Fibromyalgia: A Cross‐Sectional Study, 2025, Riquelme‐Aguado et al. ABSTRACT Introduction Fibromyalgia (FM) is a multifactorial syndrome involving chronic pain and psychological distress. Psychological traits...
  10. V

    Hypotheses and Research Directions for ME/CFS

    Jonathan, I have long wondered about the validity of this research paper on Fibromyalgia from 2013. It discusses ischemia a bit. Are you familiar with it? Excessive Peptidergic Sensory Innervation of Cutaneous Arteriole-Venule Shunts (AVS) in the Palmar Glabrous Skin of Fibromyalgia Patients...
  11. V

    Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

    It is a reformularion of flexeril (cyclobenzaprine) - a common, inexpensive muscle relaxer pharmaceutical. The study is worth perusing. I do wonder what will be the price when it rolls out in other countries.
  12. V

    Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

    For USA pricing, I did a search on "GoodRX". current pricing is listed as $1850-$2150 for a one month supply. Welcome to the wonderful world of new drug pricing! some Internet searching dug up a comment from Tonix Pharmaceuticals, the drug company selling this product. They said that it would...
  13. V

    Genetics: CA10

    what did you learn that can be shared with us?
  14. V

    Genetics: CA10

    What sort of activities do you suspect the UCL pain geneticists will undertake?
  15. V

    Circulating levels of GDF15 in patients with myalgic encephalomyelitis/chronic fatigue syndrome, 2019, Melvin, Lacerda, Nacul et al

    yes. My gdf-15 test results were negative. Normal value: <=750 pg/mL…. mine = 692 pg/mL. tests were done by the Mayo Clinic Labs in Minnesota, USA.
  16. V

    Pain Catastrophizing and its Domains Significantly Impact Rheumatoid Arthritis Disease Activity, 2025, Currado et al

    Abstract This study aims to evaluate the impact of pain catastrophizing (PC) on disease activity in patients with rheumatoid arthritis (RA) and to explore, in the same participants, if this association is related or not with anxiety and depression, which have been related to catastrophization in...
  17. V

    Is the key pathology of ME/CFS in bone marrow?

    Interesting. I experience an overwhelming"flu like ache" which at times can occur seemingly solely due to a rapidly falling barometric pressure. I live somewhere where large and steep drops in barometric pressure occur in the fall, winter and spring seasons. I have quizzed medical...
  18. V

    Targeting sodium channels — challenges for acute pain and the leap to chronic pain, 2025, Alsaloum, Vasylyev, Waxman.

    I am still reading this… this is a very good summary by some leading researchers about the difficulties they have encountered in trying to develop non-opioid painkillers using the sodium channel Nav1.8. It’s been a difficult and perplexing process and there’s an immense amount of pressure to...
  19. V

    Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

    interesting and odd. Just a reformation of Flexeril?? Here’s a link to the companies publication in the journal, “pain medicine”: https://academic.oup.com/painmedicine/advance-article/doi/10.1093/pm/pnaf089/8193722 Here is the graph from the paper of the Primary efficacy endpoint, a daily...
  20. V

    The genetic architecture of fibromyalgia across 2.5 million individuals, 2025, Kerrebijnet al.

    Abstract Fibromyalgia is a common and debilitating chronic pain syndrome of poorly understood etiology. Here, we conduct a multi-ancestry genome-wide association study meta-analysis across 2,563,755 individuals (54,629 cases and 2,509,126 controls) from 11 cohorts, identifying the first 26 risk...
Back
Top Bottom